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Impact of microRNA-130a on the
neutrophil proteome
Corinna Cavan Pedersen1*, Jan Christian Refsgaard2, Ole Østergaard3, Lars Juhl Jensen2,
Niels Henrik Helweg Heegaard3,4, Niels Borregaard1 and Jack Bernard Cowland1*
Abstract
Background: MicroRNAs (miRNAs) are important for the development and function of neutrophils. miR-130a is
highly expressed during early neutrophil development and regulates target proteins important for this process.
miRNA targets are often identified by validating putative targets found by in silico prediction algorithms one at a
time. However, one miRNA can have many different targets, which may vary depending on the context. Here, we
investigated the effect of miR-130a on the proteome of a murine and a human myeloid cell line.
Results: Using pulsed stable isotope labelling of amino acids in cell culture and mass spectrometry for protein
identification and quantitation, we found 44 and 34 proteins that were significantly regulated following inhibition
of miR-130a in a miR-130a-overexpressing 32Dcl3 clone and Kasumi-1 cells, respectively. The level of miR-130a
inhibition correlated with the impact on protein levels. We used RAIN, a novel database for miRNA–protein and
protein–protein interactions, to identify putative miR-130a targets. In the 32Dcl3 clone, putative targets were more
up-regulated than the remaining quantified proteins following miR-130a inhibition, and three significantly
derepressed proteins (NFYC, ISOC1, and CAT) are putative miR-130a targets with good RAIN scores. We also created
a network including inferred, putative neutrophil miR-130a targets and identified the transcription factors Myb and
CBF-β as putative miR-130a targets, which may regulate the primary granule proteins MPO and PRTN3 and other
proteins differentially expressed following miR-130a inhibition in the 32Dcl3 clone.
Conclusion: We have experimentally identified miR-130a-regulated proteins within the neutrophil proteome.
Linking these to putative miR-130a targets, we provide an association network of potential direct and indirect
miR-130a targets that expands our knowledge on the role of miR-130a in neutrophil development and is a
valuable platform for further experimental studies.
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Background
Neutrophils are the most abundant leukocytes in human
blood. They are essential for innate immunity and are
the first cells to be recruited for defence against invading
microorganisms at sites of infection [1]. Neutrophils are
continuously produced in the bone marrow through a
tightly regulated process termed granulopoiesis. Differ-
ent types of granules loaded with microbicidal proteins
appear at different stages of neutrophil differentiation,
which is defined by six morphologically distinguishable
cellular stages of maturation. The first morphologically
identified precursor committed to the neutrophil lineage
is the myeloblast. Myeloblasts mature into promyelo-
cytes, in which formation of primary granules containing
myeloperoxidase (MPO) takes place, and further to
myelocytes where secondary granules are formed. Prolif-
eration ceases as differentiation proceeds via the meta-
myelocyte, the band cell, and ultimately the mature
segmented neutrophil, which is the cell released to blood.
Granulopoiesis is strictly regulated by transcription factors
including RUNX1, C/EBPα, and C/EBPε [2–4].
MicroRNAs (miRNAs) are small, non-coding RNAs
that negatively regulate gene expression on a post-
transcriptional level by binding to target mRNAs, thereby
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altering translation of the transcripts or their stability.
Target recognition is mediated through base-pairing of the
miRNA with its target mRNA, usually between a 6–7
nucleotide seed sequence situated within residues 2–8 of
the miRNA and a miRNA recognition element (MRE) in
the 3′ untranslated region (3′ UTR) of the mRNA [5, 6].
The resulting changes in protein expression affect wide-
spread cellular processes including development, differenti-
ation, proliferation, survival, and immune responses [7, 8].
Alterations in miRNA levels have been associated with
numerous diseases and are implicated in the initiation and
progression of human cancers including leukemias [8].
We recently demonstrated that miRNAs are regulators of
proteins essential for granulopoiesis [9–11]. We showed
that miR-130a suppresses expression of Smad4 and thereby
reduces sensitivity to TGF-β1-induced growth inhibition
[9]. miR-130a also represses appropriate cell cycle exit and
secondary granule protein expression by targeting C/EBPε
in neutrophil precursors [9, 11]. These two targets for miR-
130a were suggested by in silico prediction algorithms
based on conservation across species, sequence comple-
mentarity, and other miRNA–mRNA binding properties
[12, 13]. This is an often-used approach to identify putative
targets of miRNAs. However, many predicted targets are
false positives, and several factors that may influence the
effect of the miRNA on the mRNA are not taken into con-
sideration [14]. These include tissue specificity, expression
levels of both RNA molecules, and the surrounding regula-
tory mechanisms particular to the cell of interest [15, 16].
More direct methods used for finding miRNA targets
include identification of changes in mRNA transcript levels
induced by altered miRNA expression and immunoprecipi-
tation of miRNA–mRNA complexes [17–21]. However,
these methods do not account for the actual reduction in
protein levels seen in a particular cell type in response to
changes in expression of an endogenous miRNA. Protein
turnover times vary, and repression of gene expression by
miRNAs can occur solely through translational inhibition,
altering only the amount of protein being produced and
not the amount of mRNA [9]. Immunoblotting is fre-
quently used to determine the effect of miRNA-mediated
reduction on synthesis of selected proteins. As an alterna-
tive for a more extensive, global characterization of the
effects of miRNA modulations on protein expression, stable
isotope labelling of amino acids in cell culture (SILAC) and
mass spectrometry (MS) may be used as originally shown
[22] and applied to the neutrophil proteome in a murine
model [23]. Further developments of the approach include
pulsed SILAC (pSILAC), in which only newly synthesized
proteins are labelled as shown in the analysis of around
5000 proteins in HeLa cells [18].
Here, we used pSILAC-based MS to investigate the
effects of miR-130a on the neutrophil proteome using
two myeloblast-derived cell lines: murine 32Dcl3 cells
and human Kasumi-1 cells. miR-130a is highly expressed
in early neutrophil precursors (myeloblasts and promyelo-
cytes) compared to more mature precursors [9, 10]. We
demonstrate that inhibition of miR-130a with an anti-
miR-130a oligonucleotide in a miR-130a-overexpressing
32Dcl3 clone and in Kasumi-1 cells results in significant
changes in the levels of 44 out of 2092 proteins and 34
out of 1238 proteins, respectively. We found that putative
miR-130a target proteins are more induced than the
remaining proteins quantified in the 32Dcl3 miR-130a
clone following miR-130a inhibition. Three significantly
induced proteins, nuclear transcription factor Y, gamma
(NFYC), isochorismatase domain containing 1 (ISOC1),
and catalase (CAT), are putative miR-130a targets with
good scores in RAIN (RNA–protein Association and
Interaction Networks) [http://rth.dk/resources/rain/]. Fi-
nally, we constructed miR-130a target protein networks
including the proteins identified in this study in order to
find pathways affected by miR-130a in the context of neu-
trophil development. We identified important myeloid
regulatory proteins, such as Myb and Core-binding factor
beta (CBF-β), as putative direct miR-130a targets.
Methods
Cell culture, transfection, and pSILAC labelling
The sequences of murine and human miR-130a-3p
(miR-130a) are identical. The murine myeloblast-derived
cell line 32Dcl3 (ATCC® CRL-11346) was stably trans-
fected with the expression plasmid pEGP-miR-130a (Cell
Biolabs) as described previously [9]. This 32Dcl3 miR-
130a clone was cultured in SILAC medium consisting of
RPMI medium without arginine, lysine, and glutamine
(PAA Cell Culture Company), 10 % dialysed FBS
(Gibco), 100 U/mL penicillin and 100 μg/mL strepto-
mycin (Gibco), 1 ng/mL murine IL-3 (Sigma-Aldrich),
1 % GlutaMAX™-1 (Gibco), and 0.2 mg/mL proline
(Sigma-Aldrich) to avoid arginine-to-proline conversion
[24]. Either naturally occurring isotopes of lysine and
arginine (light (L)), 4,4,5,5-D4-lysine and
13C6-arginine
(Lys4 & Arg6, medium-heavy (M)), or 13C6,
15N2-lysine
and 13C6,
15N4-arginine (Lys8 & Arg10, heavy (H)) were
added to the medium at a concentration of 48.67 mg/L
for lysine and 28 mg/L for arginine.
For pSILAC, the 32Dcl3 miR-130a clone was grown in
SILAC L medium for six days and subsequently washed
twice with phosphate-buffered saline (PBS) to eliminate
traces of L amino acids. Cells (5x106/condition) were then
transfected with anti–miR-130a-LNA or scrambled-LNA
(Exiqon) through electroporation using the AMAXA
nucleofection system (program E-032) according to the
manufacturer’s recommendations and transferred to M
(anti–miR-130a-LNA) or H (scrambled-LNA) medium for
approximately 48 h. Similarly, Kasumi-1 cells (human
myeloblast cell line derived from a patient with acute
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myeloblastic leukemia, ATCC® CRL-2724) were grown in
normal medium (RPMI1640 (Gibco), 20 % FBS (Gibco),
100 U/mL penicillin and 100 μg/mL streptomycin
(Gibco)), washed twice with PBS before transfection (pro-
gram C-23) with anti–miR-130a-LNA or scrambled-LNA
(Exiqon) and switched to M or H SILAC medium, re-
spectively, for approximately 72 h. The SILAC medium
used for Kasumi-1 cells was identical to the 32Dcl3 SILAC
medium except 20 % dialysed FBS was used and no IL-3
was added.
RNA and protein extraction and quantification
Kasumi-1 cells were centrifuged on a Histopaque 1.077
gradient (400 g, 4 °C, 30 min) to remove dead cells. Both
cell lines were washed twice in PBS and counted with an
automatic cell counter (Coulter Z1; Beckman). Viability
was evaluated using trypan blue (Sigma-Aldrich) exclu-
sion. Total RNA was extracted from cells from each
condition with the PureLink RNA Mini Kit (Ambion)
according to the manufacturer’s recommendations. M
and H conditions were combined 1:1 based on cell
counts. For protein extraction, cell combinations were
lysed in preheated, non-reducing 2x Laemmli sample
buffer (125 mM Tris–HCl pH 6.8, 4 % SDS, 20 %
glycerol) supplemented with cOmplete Mini Protease
Inhibitor Cocktail (Roche) and boiled for 10 min. Pro-
tein concentration was measured using the Pierce BCA
Protein Assay kit (Thermo Scientific).
cDNA synthesis and miRNA detection
Reverse transcription of miRNA to first-strand cDNA was
performed using the primers miR-130a (RT454) with
SNO234 (RT1234, Applied Biosystems) and RNU6B
(RT1093, Applied Biosystems) as internal normalizers in
32Dcl3 and Kasumi-1 cells, respectively. Real-time PCR
was performed in triplicate using TaqMan MicroRNA As-
says (20x) (all Applied Biosystems) for miR-130a (RT454)
with SNO234 (RT1234) and RNU6B (RT1093) as controls
on a 3000-P real-time PCR machine (Stratagene).
In-solution digestion
From the cell lysate, 50 μg of protein were precipitated
using trichloroacetic acid/acetone followed by protein re-
solubilization in 10 μL 8 M urea, 50 mM NH4HCO3. The
re-solubilized protein was subsequently reduced by incu-
bation with dithiothreitol (10 mM final concentration,
30 min, room temperature) followed by alkylation with
iodoacetamide (50 mM final concentration, 30 min in the
dark at room temperature). The alkylated proteins were
next pre-digested for three hours using endo-Lys C (final
concentration 0.5 μg endo-Lys C/50 μg protein; Waco
Pure Chemical Industries) before dilution to a final con-
centration of 2 M urea and continued digestion overnight
at room temperature using trypsin (final concentration
1 μg trypsin/50 μg protein, Promega). Peptides were then
depleted for SDS using Pierce Detergent Removal Spin
Columns (Thermo Scientific, Rockland, IL, USA) before
OFFGEL peptide fractionation.
OFFGEL peptide fractionation
Tryptic peptides were fractionated according to their iso-
electric points into 12 fractions by OFFGEL fractionation
on a 13 cm immobilized pH gradient strip (pH 3-10NL,
GE Healthcare) using a 3100 OFFGEL separator (Agilent
Technologies). Fractions were collected into Eppendorf
tubes and dried down to a final volume of 20 μL using a
vacuum concentrator (Eppendorf) before freezing or fur-
ther processing.
Peptide desalting using StageTips
Concentrated OFFGEL fractions were diluted with 5 %
formic acid and desalted on a pre-equilibrated home-
made StageTip essentially as described previously [25].
The desalted peptides were then incubated in a vacuum
concentrator (Eppendorf) to almost complete dryness
for methanol removal and then re-dissolved into 20 μL
5 % formic acid and transferred to a glass vial for further
analysis by MS.
Peptide analysis by LC-MS/MS
Five microliters of the desalted OFFGEL peptide fractions
were loaded on an Acclaim PepMap100 C18 precolumn
(100 μm x 2 cm, 5 μm particle size, 100 Å, Thermo Fischer
Scientific). Proteins were separated using an EASY-spray
PepMap100 C18 analytical column with integrated emitter
(75 μm inner diameter, 150 mm long, 3 μm particle size,
100 Å, Thermo Fisher Scientific) on a 90-min gradient con-
trolled by an Easy-nLC II (Thermo Fisher Scientific). The
column was connected to an LTQ Orbitrap XL mass spec-
trometer (Thermo Fisher Scientific) equipped with an
EASY-spray nano-electrospray source (Proxeon, Odense,
Denmark). The flow rate was 200 nL/minute; the mobile
phases consisted of solvent A (2 v/v % acetonitrile, 0.1 %
formic acid) and solvent B (95 v/v % acetonitrile, 0.1 % for-
mic acid v/v). The gradient went from 0 % to 45 % solvent
B in 80 min, followed by 10 min with 100 % solvent B; then
data acquisition was stopped and the column was re-
equilibrated with solvent A. MS data were acquired record-
ing full scan spectra (300–1800 mass/charge [m/z]) in the
Orbitrap with 60,000 resolution at 400 m/z. MS/MS data
were recorded in parallel in a data-dependent mode, frag-
menting the 5 most abundant ions (charge state +2 or
higher) by collision-induced dissociation in the LTQ ion
trap at 35 % collision energy. MS/MS spectra were
recorded using dynamic exclusion (30 s) to minimize
repeated fragmentation of the same peptides.
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Data analysis using MaxQuant
Recorded raw files were analysed using MaxQuant version
1.1.1.36 [26] for peptide quantitation by MS1-intensity
and for protein identification using the Andromeda search
engine [27] with the following settings: FASTA-files:
Homo_sapiens.GRCh37.73.pep.all.fasta (Kasumi-1 cells)
or Mus_musculus.GRCm38.73.pep.all.fasta (32Dcl3 cells).
Variable modifications: oxidation (M), acetyl (protein N-
terminal), fixed modifications: carbamidomethyl (C). La-
bels: Arg6 & Lys4 as medium-labelled and Arg10 & Lys8
as heavy-labelled amino acids. Peptide false discovery rate
(FDR): 1 %. Protein FDR: 1 %. Match between runs: 2 min.
Keep low-scoring version of identified peptides: on. All
other settings were left at their defaults.
Data analysis of proteins identified by LC-MS/MS
Significantly regulated proteins were determined by per-
forming a Significance B test [26] with a window size of 900
and step size of 300 proteins (for more information see Add-
itional file 1: Supplemental methods and Additional file 2:
Figure S1). Assigned p-values were corrected for multiple
testing using the Benjamini–Hochberg procedure [28]. Pro-
teins with a resulting corrected p-value (q) <0.01 were
deemed significantly regulated. Each protein was assigned a
human readable HGNC (HUGO Gene Nomenclature Com-
mittee) or MGI (Mouse Genome Informatics) symbol via
Ensembl BioMart version 0.7 [29].
Each protein was assigned a miR-130a association
probability by mapping to RAIN [http://rth.dk/re-
sources/rain/] via the STRING 10 alias file. For miRNA
target identification, RAIN incorporates experimentally
supported interactions (miRTarBase [30], NPInter [31],
StarBase [32]), miRNA and mRNA co-occurrence-based
text mining of Medline abstracts [33], as well as proc-
essed miRNA target predictions from the prediction
algorithms TargetScan [34], PicTar [35], miRanda [12],
and StarMirDB [36]. Based on these inputs, the program
assigns association probabilities to potential targets of a
given miRNA according to the combined level of confi-
dence of the miRNA–mRNA interaction. RAIN obtains
all protein–protein interactions from STRING [37].
The proteins identified in MS were compared with the
top 20 % best scoring RAIN association probabilities for
miR-130a to a) find potential miR-130a targets among
the quantified proteins for the two cell lines, and to b)
identify potential miR-130a target proteins for the miR-
130a association network that might associate with pro-
teins within the regulated protein subset found for the
32Dcl3 miR-130a clone. Cytoscape [38] was used to
visualize this network. The DAVID tool [39, 40] was
used to identify enriched Gene Ontology terms for cellu-
lar components, and the Ingenuity Pathway Analysis
software (QIAGEN, http://www.qiagen.com/ingenuity)
was used to identify enriched ‘Molecular and Cellular
Functions’ among regulated proteins compared to the
remaining quantified proteins within the same experiment.
Results and discussion
miR-130a expression in the 32Dcl3 and Kasumi-1 cell
lines
Our aim was to evaluate the effect of miR-130a on the
proteome at the time of neutrophil maturation when miR-
130a expression is at its peak (myeloblasts and promyelo-
cytes) [9]. We therefore chose a murine and a human cell
line both representing immature neutrophil precursors.
The murine myeloblast-derived cell line 32Dcl3 was stably
transfected with a miR-130a-expressing plasmid, resulting
in a clone over-expressing miR-130a. This has previously
been shown to be a good model for investigating the effect
of miR-130a on specific target proteins [9, 11]. The
Kasumi-1 cell line is derived from an acute myeloid
leukemia patient with t(8;21)(q22;q22) chromosomal trans-
location and has a 2.5-fold higher endogenous expression
of miR-130a than the level found in primary myeloblasts
and promyelocytes isolated from normal human bone mar-
row [9].
pSILAC approach for identification of myeloid miR-130a
target proteins
We transiently transfected the 32Dcl3 miR-130a clone
and Kasumi-1 cells with an inhibitory LNA probe
against miR-130a (anti-miR-130a-LNA) or a scrambled-
LNA (mock transfection). The cells were then transferred
to medium-heavy (M) and heavy (H) medium,
respectively, and pulsed for approximately 48 h (32Dcl3)
or 72 h (Kasumi-1). At this point, the effect of miR-130a
is reflected by differences between M and H proteins
while light (L) proteins have all been synthesized prior to
interference with the free miR-130a pool. Subsequently,
cells from each condition were combined in equal
amounts, lysed, and prepared for analysis on the LTQ
Orbitrap XL mass spectrometer after extensive fraction-
ation as described in Methods. The experimental setup is
outlined in Fig. 1. The free pool of miR-130a at the time
of harvest was measured using real-time PCR and indi-
cates the different levels in the anti-miR-130a-LNA and
scrambled-LNA conditions (Additional file 3: Figure S2).
Impact of miR-130a on protein output
For the 32Dcl3 miR-130a clone, we identified a total of
2092 proteins present both in the M and H condition
and their ratios could be quantified. For the Kasumi-1
cells, this number was 1238 proteins, possibly reflecting
the slower growth and incorporation of new amino acids
in these cells. Additional file 4 lists the complete sets of
quantified proteins and related parameters, and Fig. 2
shows the intensities in MS as a function of log2 fold
changes in protein expression. Proteins differentially
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regulated by miR-130a were determined based on statis-
tical significance rather than a fold change cut-off. In
this manner, differences in noise at different levels of
intensities within the MS analysis were taken into con-
sideration. Moreover, the effect of miRNAs can be rather
subtle [18] and might not amount to e.g. a two-fold
change in target protein levels. After correction for
multiple testing, we identified 31 up-regulated and 13
down-regulated proteins in the 32Dcl3 miR-130a clone,
and 19 up-regulated and 15 down-regulated proteins in
Kasumi-1 cells, following miR-130a inhibition (q < 0.01).
Biological characteristics of neutrophil miR-130a-
regulated proteins
We investigated the biological characteristics of the
regulated protein subset in the 32Dcl3 miR-130a clone.
Lysosomes and peroxisomes were found by DAVID to
be enriched cellular components in the regulated subset
compared to all quantified proteins. Using the Ingenuity
Pathway Analysis software, we also found that ‘cellular
development’ and ‘cellular growth and proliferation’ were
the two most enriched ‘Molecular and Cellular Func-
tions’ in the regulated subset compared to the remaining
quantified proteins. This corresponds well with observed
effects of miR-130a on proliferation and cell cycle in im-
mature neutrophil cells [9, 11].
Identification of miR-130a targets in the neutrophil
proteome
The standard way to validate the impact of a miRNA in a
proteomics study is to search for an enrichment of matches
to the miRNA seed sequence within the 3′ UTRs of the
mRNAs encoding proteins found to be regulated within the
experiment [41, 42]. However, several other aspects of the
miRNAs and of their target mRNAs are involved in their
interaction, including mRNA accessibility and complemen-
tarity between the remaining miRNA sequence and the
mRNA target [43]. Different in silico miRNA target predic-
tion algorithms take these and other aspects into consider-
ation to various extents, resulting in algorithms with
distinct specificity and sensitivity and, consequently, varying
reliability in their identification of potential miRNA targets
[44]. While the seed sequence is commonly accepted as be-
ing an indispensable part of the interaction mechanism [6],
its presence alone grossly overestimates the number of tar-
gets for a given miRNA [44]. We therefore used a novel
tool, RAIN [http://rth.dk/resources/rain/], to identify
potential direct miR-130a targets among the proteins found
Fig. 1 Experimental setup of the pSILAC method. a Cells grown in L medium were transfected with anti-miR-130a-LNA or scrambled-LNA (mock-transfec-
tion) and transferred to M or H SILAC-medium, respectively. After 48 h (32Dcl3 miR-130a clone, doubling time ~18–20 h) or 72 h (Kasumi-1, doubling time
~40 h) of pulse labelling, cells were washed, combined 1:1, and lysed. Samples were prepared for and analysed by LC-MS/MS, producing peptide peaks as
shown (b). The light peptides were disregarded while the M and H peptides were compared, generating M/H ratios for further analysis
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within our two studies (see Methods for details). As most
of the associations come from prediction algorithms, we
chose the top 20 % highest scoring associations, which con-
sist of 678 predictions, 5 experiments, and 6 text-mining in-
teractions for miR-130a in mice.
First, we used RAIN to determine whether changes
in protein levels could be directly attributed to the
inhibition of miR-130a. We compared the fold
changes of potential miR-130a target proteins with a
good RAIN score (top 20 %) to those of proteins
without scores (Fig. 3). We found potential targets to
be more up-regulated after miR-130a inhibition for
the 32Dcl3 miR-130a clone (Kolmogorov–Smirnov
test, p-value = 0.018) as demonstrated by the right
shift of the curve showing higher M/H ratios. The
effect was not present for the Kasumi-1 cells (not
shown). This confirms that there is an overall greater
effect of inhibiting miR-130a in cells from the 32Dcl3
miR-130a clone where the free miR-130a pool is
much more reduced (~31 fold reduction) than in the
Kasumi-1 cell line (~2.3 fold reduction) upon LNA-
mediated inhibition (Additional file 3: Figure S2).
Secondly, we used RAIN to determine potential miR-
130a targets within the subsets of significantly regulated
proteins. Three derepressed proteins (NFYC, ISOC1,
and CAT) with miR-130a association probabilities within
the top 20 % were found in the 32Dcl3 miR-130a clone
and one (Phosphatidylinositide phosphatase SAC1,
SACM1L) in Kasumi-1 cells (Fig. 2), indicating that most
of the de-regulated proteins are either indirectly regu-
lated by miR-130a or bona fide miR-130a targets not
found by RAIN.
In MS experiments, such as the one described here,
typically only a minor fraction of the proteins present in
the cell is detected [45]. The number is further limited
by the requirement for detection of both M and H
proteins to identify ratios between conditions. This may
also explain the fact that the subsets of significantly
regulated proteins did not overlap between the two cell
lines. Proteins in the regulated subset in one cell line
identified for both the H and M condition among non-
significantly regulated proteins in the other cell line are
listed in Additional file 5: Table S1.
In MS the capacity to detect proteins of low abun-
dance, such as transcription factors and other regulatory
proteins, is limited in samples with a high dynamic
range [45–47]. In contrast, miRNAs favour transcription
factors, which are generally expressed at relatively low
levels in the cell [47], as targets [33]. C/EBPε is not
expressed in 32Dcl3 or Kasumi-1 cells (data not shown),
and Smad4 was not identified in either cell line. Conse-
quently, a small change in the protein level of, for
example, a transcription factor may have a greater and
thus detectable downstream effect. Together RUNX1
and CBF-β constitute an important heterodimeric, mye-
loid transcription factor. CBF-β is a highly predicted
miR-130a target (top 20 %). CBF-β is up-regulated
1.35-fold (although not statistically significant) in the
32Dcl3 miR-130a clone following miR-130a inhibition
and a candidate upstream regulator of three proteins
within the regulated subset: MPO, IL-2Ra (Ingenuity
Pathway analysis) and proteinase 3 (PRTN3, author
observations, unpublished). Of these three only MPO
and PRTN3 were identified in the Kasumi-1 experi-
ment, and only PRTN3 was borderline significantly
up-regulated (q = 0.0113), probably reflecting the
greater degree of miR-130a inhibition by anti-miR-
130a-LNA observed in the 32Dcl3 miR-130a clone
(Additional file 3: Figure S2).
Fig. 2 The intensities in MS as a function of log2 fold changes in
protein expression between the anti–miR-130a-LNA and scrambled-LNA
conditions for the 32Dcl3 miR-130a clone (a) and the Kasumi-1 cells
(b). Proteins are represented by crosses (miR-130a association probability
in top 20 %) or dots (miR-130a association probability below top 20 % or
no score). Colours represent significance according to the Significance B
test (Benjamini-Hochberg corrected). Significantly regulated proteins with
q < 0.01 and top 20 % miR-130a association probabilities are given
by name
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To identify additional potential regulatory networks in-
volving miR-130a, we constructed association networks
for the subset of 44 regulated proteins found for the
32Dcl3 miR-130a clone. Other proteins that interact with
this protein subset with protein-protein association prob-
abilities above 0.7 and which have miR-130a association
probabilities within the top 20 % were also included. This
resulted in a major miR-130a network as well as several
minor, disconnected networks (Fig. 4). The major miR-
130a network includes the transcriptional activator Myb,
which is more highly expressed in early neutrophil precur-
sors compared to more mature cells [48]. Myb is a pre-
dicted miR-130a target but was not identified in either cell
line. If Myb is up-regulated following inhibition of miR-
130a, this could lead to the observed increases of its
targets, the primary granule proteins MPO [49] and
PRTN3 [50] (Fig. 4). Therefore, both CBF-β and Myb are
potential direct miR-130a targets worth investigating
further. CBF-β, Myb, and miR-130a are co-expressed in
early myeloid precursors, suggesting that miR-130a may
have a buffer effect on their protein levels ([48, 51] and
unpublished data).
In murine cells, RAIN does not identify Smad4 as a
miR-130a target. TargetScan identifies Smad4 as a hu-
man miR-130a target with two seed matches (MREs) in
the Smad4 3′ UTR. The same MREs are also found in
the murine Smad4 3′ UTR, but presumably other fac-
tors of the TargetScan algorithm prevent its prediction
of murine Smad4 as a miR-130a target since murine and
human miR-130a are identical. We have previously ex-
perimentally identified Smad4 as a direct miR-130a tar-
get in murine cells [9]. However, Medline abstracts and
experimental databases in RAIN only include murine
targets if it is explicitly stated that they are derived from
experiments with murine cells. Therefore, it cannot be
excluded that certain interesting miR-130a targets will
be missed using RAIN due to this restriction in the
underlying databases. RAIN does identify a weak inter-
action, although below the network cut-off, between
Smad4 and NFYC, which is significantly up-regulated
upon miR-130a inhibition. NFYC is a predicted miR-
130a target, but the effect of miR-130a might also be
mediated by Smad4 or one of its other associated net-
work proteins such as its heterotrimeric transcription
factor complex partner NFYA. This complex plays an
important role in cell cycle progression [52] and may
thus be regulated in neutrophil precursors by miR-130a
targeting two of its subunits.
Not much is known about ISOC1, also significantly
derepressed by miR-130a inhibition and a highly predicted
miR-130a target, other than that it associates with peroxi-
somes, has enzymatic activity, and may promote cell
growth [53, 54]. The last miR-130a target with a good
RAIN score and significantly derepressed protein in the
32Dcl3 miR-130a clone is CAT. CAT is also usually located
within peroxisomes and catalyses hydrogen peroxide
degradation [55]. The significantly down-regulated
Smarcb1 associates with Smarcd2, which is a predicted
Fig. 3 The cumulative distributions of M/H ratios of proteins with good RAIN scores (top 20 %, green), all remaining proteins (black), and proteins
without RAIN scores (orange) as a function of log2 M/H fold changes in protein expression between the anti-miR-130a-LNA (M) and scrambled-LNA
(H) conditions for the 32Dcl3 miR-130a clone. A Kolmogorov-Smirnov test of equality between distributions results in the following: p-value = 0.018 for
the comparison between M/H ratios of proteins with good RAIN scores and the M/H ratios of proteins without scores; p-value = 0.042 for the M/H
ratios of proteins with good RAIN scores and the M/H ratios of all remaining proteins
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miR-130a target and down-regulated, although not signifi-
cantly, in this study. These proteins form parts of SWI/SNF
complexes, which regulate gene expression through chro-
matin remodelling [56]. This indicates that, in addition to
transcription factors, miR-130a may target other types of
transcriptional regulators as well as metabolic processes in
neutrophil precursors. In summary, these and other
interactions identified here can form the basis for further
experimental identification of miR-130a regulation in neu-
trophil development extending further than just single
miR-130a–mRNA interactions.
Conclusion
We identified subsets of the murine and human neutro-
phil proteomes significantly regulated by miR-130a, which
likely represent a mixture of direct targets, including
NFYC, ISOC1, and CAT, and mainly indirect miR-130a
targets. We demonstrated that substantial inhibition of
miR-130a affects the overall expression of predicted target
proteins in the murine neutrophil model system. We iden-
tified common biological features of the significantly
regulated murine protein subset. Combining the signifi-
cantly regulated murine protein subset with high-scoring
putative miR-130a targets from the RAIN database in an
interaction network, we identified subsets of proteins with
potential roles in downstream miR-130a regulation rele-
vant for further experimental investigation. Based on these
analyses, we identified Myb and CBF-β as putative direct
miR-130a targets and potential regulators of the primary
granule proteins MPO and PRTN3 following miR-130a
Fig. 4 RAIN networks of potential miR-130a targets (with miR-130a association probabilities in the top 20 %) and differentially regulated proteins
identified for the 32Dcl3 miR-130a clone following miR-130a inhibition. Only proteins with STRING association probabilities above 0.7 and interactions
with significantly regulated proteins are included. Square: predicted target (= top 20 %). Oval: not predicted. Bold outline: in dataset and significant.
Thin outline: in dataset but not significant. No outline and blue: not in dataset. Red: up-regulated >0.3 (log2 ratio) upon miR-130a inhibition. Green:
down-regulated < −0.3 (log2 ratio) upon miR-130a inhibition. Grey: regulated less than 0.3 (log2 ratio). These fold changes are included in the network
to also indicate the observed direction of strongly predicted targets quantified but not significantly regulated within the data set
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inhibition in the 32Dcl3 miR-130a clone. Together, these
results provide significant insight into multiple miR-130a-
regulated proteins and emphasize its important regulatory
role in neutrophil development.
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